Yesterday, Barr Laboratories' stock price rose about 2% upon this news:
The FDA confirmed that it sent a letter to Duramed "to proceed working with the sponsor in order to move Plan B [the "morning-after" abortifacient] from prescription only to over-the-counter status for women ages 18 and older."The company expects Plan B to start at $35 MILLION and grow to $200 MILLION annually. (How many babies does that dollar figure represent?)
Equally despicable: politicking at the expense of innocent lives.
How do these people sleep at night?The FDA's decision to move forward on Plan B talks could result in the permanent appointment Tuesday of Andrew von Eschenbach, acting commissioner of the FDA. Two senators have said they will block the nomination if the FDA continues to drag its feet on Plan B.
"In order for Eschenbach to get approval, this needs to get out of the way," said Forman.